Abbvie Inc (NYSE: ABBV)’s stock price has gone rise by 1.25 in comparison to its previous close of 167.90, however, the company has experienced a -6.64% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-05 that AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock’s prospects.
Is It Worth Investing in Abbvie Inc (NYSE: ABBV) Right Now?
The price-to-earnings ratio for Abbvie Inc (NYSE: ABBV) is above average at 62.49x, Company’s 36-month beta value is 0.58.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 4 as “overweight,” 10 as “hold,” and 0 as “sell.”
The public float for ABBV is 1.76B, and currently, short sellers hold a 0.83% ratio of that floaft. The average trading volume of ABBV on April 08, 2024 was 5.65M shares.
ABBV’s Market Performance
ABBV stock saw a decrease of -6.64% in the past week, with a monthly decline of -6.11% and a quarterly a decrease of 5.29%. The volatility ratio for the week is 2.82%, and the volatility levels for the last 30 days are 1.74% for Abbvie Inc (ABBV). The simple moving average for the last 20 days is -4.93% for ABBV’s stock, with a simple moving average of 10.14% for the last 200 days.
ABBV Trading at -3.15% from the 50-Day Moving Average
After a stumble in the market that brought ABBV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.05% of loss for the given period.
Volatility was left at 1.74%, however, over the last 30 days, the volatility rate increased by 2.82%, as shares sank -5.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.52% upper at present.
During the last 5 trading sessions, ABBV fell by -6.64%, which changed the moving average for the period of 200-days by +23.35% in comparison to the 20-day moving average, which settled at $178.28. In addition, Abbvie Inc saw 9.70% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABBV starting from Donoghoe Nicholas, who sale 21,082 shares at the price of $176.30 back on Mar 20 ’24. After this action, Donoghoe Nicholas now owns 55,903 shares of Abbvie Inc, valued at $3,716,757 using the latest closing price.
Stewart Jeffrey Ryan, the EVP, CHIEF COMMERCIAL OFFICER of Abbvie Inc, sale 58,949 shares at $178.79 during a trade that took place back on Mar 18 ’24, which means that Stewart Jeffrey Ryan is holding 60,941 shares at $10,539,508 based on the most recent closing price.
Stock Fundamentals for ABBV
Current profitability levels for the company are sitting at:
- 0.26 for the present operating margin
- 0.69 for the gross margin
The net margin for Abbvie Inc stands at 0.09. The total capital return value is set at 0.15. Equity return is now at value 34.90, with 3.52 for asset returns.
Based on Abbvie Inc (ABBV), the company’s capital structure generated 0.85 points at debt to capital in total, while cash flow to debt ratio is standing at 0.38. The debt to equity ratio resting at 5.73. The interest coverage ratio of the stock is 7.54.
Currently, EBITDA for the company is 18.1 billion with net debt to EBITDA at 2.55. When we switch over and look at the enterprise to sales, we see a ratio of 6.39. The receivables turnover for the company is 4.87for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.87.
Conclusion
In a nutshell, Abbvie Inc (ABBV) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
